[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multivessel-coronary-artery-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multivessel-coronary-artery-disease":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,39,70,93,131,157,188,226,256,282,309,344,372,398,423],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100639815","insights-from-the-fast-track-cabg-trial-a-clinical-outcome-study-in-patient-with-previous-surgical-revascularization-for-complex-three-vessel-or-left-main-coronary-artery-disease-based-on-coronary-computed-tomography-angiogram-and-fractional-flow-reserve-derived-by-computed-tomography-100639815",false,"NCT07628270","Insights From the FAST-TRACK CABG Trial: a Clinical Outcome Study in Patient With Previous Surgical Revascularization for Complex Three-vessel or Left Main Coronary Artery Disease Based on Coronary Computed Tomography Angiogram, and Fractional Flow Reserve Derived by Computed Tomography","FAST-CABG: Insights From the FAST-TRACK CABG Trial: a Clinical Outcome Study in Patient With Previous Surgical Revascularization for Complex Three-vessel or Left Main Coronary Artery Disease Based on Coronary Computed Tomography Angiogram, (CCTA) and Fractional Flow Reserve Derived by Computed Tomography (FFRCT)","FAST-CABG","Inclusion Criteria:\n\n* Patients who have analyzable pre-CABG CCTA imaging and received a successful CCTA-guided plus FFRCT CABG procedure.\n* Patient with known level of Lp(a) or with possibility to perform the test\n* Patent able to provide written informed consent as approved by the Ethical Committee\n\nExclusion Criteria:\n\n* Patients without pre-CABG CCTA imaging or those with who did not receive surgical revascularization.\n* Current treatment with lipoprotein apheresis\n* Patients who refuse to receive clinical follow-up\n* Unable to give Informed Consent","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","Coronary computed tomography angiography (CCTA) is a non-invasive imaging tool that characterizes coronary artery anatomy and provides detailed assessments of plaque morphology, composition , inflammation, and hemodynamics, which have crucial prognostic implications. The FASTTRACK CABG trial demonstrated that CCTA- fractional flow reserve derived from CCTA can plan and guide coronary artery bypass grafting treatment without traditional invasive coronary angiography and provides a valuable dataset of pre- and post-CABG CCTA for further research. This study is a sub-analysis of the FASTTRACK CABG trial and aims first of all to assess whether these imaging-derived markers can predict symptomatic relief and clinical outcomes for patients undergoing CABG, for complex three-vessel or left main coronary artery disease. Moreover, human coronary lesion studies from subjects with sudden death and carotid endarterectomy specimens demonstrate increasing levels of Lipoprotein(a) with lesion progression, peaking in ruptured plaques. Lp(a) is a low-density lipoprotein (LDL)-like particle comprising an apolipoprotein (apoB-100 molecule covalently linked to apo(a). Genome-wide association and Mendelian randomization studies provide strong evidence for the causal association between elevated Lp(a) levels and atherosclerotic cardiovascular diseases (ASCVD) risk. Current clinical guidelines, including the 2022 European Atherosclerosis Society (EAS) consensus, recommend measuring Lp(a) levels at least once in an adult's lifetime. Circulating Lp(a) levels remain relatively stable over a lifetime, making single measurements cost-effective for risk assessment. Established thresholds for high-risk Lp(a) levels are \\>50 mg\u002FdL or 125 nmol\u002FL, as recognized by assays standardized to WHO\u002FInternational Federation of Clinical Chemistry guidelines. Epidemiological data suggest that Lp(a) \\>30 mg\u002FdL increases the risk of coronary heart disease and myocardial infarction, while levels \\>50 mg\u002FdL elevate the risk of ischemic stroke. Approximately 20-25% of the general population has elevated serum Lp(a) levels. Despite robust evidence linking Lp(a) to ASCVD risk, data correlating Lp(a) levels with coronary artery calcium (CAC) progression remain limited. While Lp(a) and CAC independently predict ASCVD risk, their combined role in guiding prevention strategies is underexplored. Lipoprotein(a)-lowering strategies are currently being investigated in phase 3 cardiovascular outcomes trials. Specifically, the correlation between serum Lp(a) levels and CCTA-derived total calcified plaque volume has yet to be comprehensively studied.",[25],"Multivessel Coronary Artery Disease","RECRUITING","2026-06-04",{"date":29,"type":30},"2026-06-05","ACTUAL",{"date":32,"type":30},"2025-09-01",{"date":34,"type":21},"2026-05-31",{"name":36,"class":37},"Centro Cardiologico Monzino","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":56,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":38},"100639617","the-core---fr-clinical-trial-100639617","NCT07598565","The CORE - μFR Clinical Trial","μFR -Guided Complete Revascularization in Patients With Acute Coronary Syndromes","Inclusion Criteria:\n\n1. Patients presenting with ACS within 72 hours of successful culprit PCI\n2. Residual coronary artery disease, defined as at least one additional stenosis in any non-culprit vessel (NCV) with the following characteristics:\n\n   1. at least 50% diameter stenosis by visual assessment\n   2. a vessel diameter of at least 2.5 mm\n   3. amenable to successful PCI\n\nExclusion Criteria:\n\n1. Cardiogenic shock or severe heart failure (NYHA class ≥III)\n2. Severely impaired renal function: creatinine \\>2 mg\u002Fdl or estimated glomerular filtration rate (eGFR) \\\u003C30 ml\u002Fmin\u002F1,73 m²\n3. Allergy to iodine-containing contrast agents which cannot be adequately pre-medicated\n4. Pregnancy or intention to become pregnant during the trial\n5. Life expectancy less than one year\n6. Ambiguity in the identification of the culprit vessel\u002Flesion\n7. Clinical presentation as myocardial infarction and non-obstructive coronary artery disease (MINOCA) and\u002For Tako-Tsubo Syndrome\n8. Any ambiguity in the diagnosis of ACS\n9. Inability to provide informed consent\n10. Patients with only one coronary artery lesion with diameter stenosis \\>90% and\u002For TIMI flow \\\u003C3\n11. Patients in whom the NCV is treated at the time of the index procedure\n12. An interrogated lesion is at the site of a myocardial bridge\n13. An interrogated lesion is a culprit lesion responsible for the acute myocardial infarction\n14. An interrogated lesion is in a bypass graft\n15. Poor angiographic image quality precluding vessel contour detection or with suboptimal contrast opacification\n16. Severe vessel overlap in the stenosed segment or severe tortuosity of any interrogated vessel deemed not amenable to μFR measurement",{"count":47,"type":21},350,"INTERVENTIONAL",[50],"NA","Acute coronary syndromes (ACS) are frequently associated with multivessel coronary artery disease (CAD), and current guidelines recommend complete revascularization beyond the culprit lesion. Angiography-guided PCI is the standard approach, but anatomical assessment does not always reflect the functional significance of intermediate lesions, while FFR-guided strategies are limited by the need for pressure wires and hyperemia. Murray-law-based quantitative flow ratio (μFR) is a wire-free angiography-derived physiological index that may improve decision-making for revascularization in ACS patients.\n\nThe Core-μFR is an investigator-driven, multicenter, randomized, open-label and prospective trial designed to evaluate whether μFR can act as a gatekeeper for complete revascularization in patients with ACS and multivessel disease by identifying non-culprit lesions that truly require PCI.\n\nPatients with ACS (either STEMI or NSTE-ACS) undergoing primary PCI will be considered eligible if they present multivessel CAD on visual assessment with the intention to treat the non-culprit vessel in a staged procedure within the same hospitalization. After the pPCI, eligible patients will be randomized to either group A or group B and μFR will be performed in a blinded fashion with the operator unaware of the functional result. Patients in group A will undergo a staged PCI of all NCVs guided by coronary angiography, as per standard of care. In group B, μFR will be used as a gatekeeper for staged revascularization. Operators will only be informed whether at least one non-culprit vessel is μFR-positive, without disclosure of the specific vessel involved or the μFR values. If at least one non-culprit vessel has μFR ≤0.80, patients will undergo angiography-guided PCI of all non-culprit vessels previously deemed suitable for treatment by visual assessment. If μFR is \\>0.80 in all non-culprit vessels, staged PCI will be deferred and the patient will be discharged without further revascularization. Finally, to test the functional reproducibility, a blinded post-hoc μFR assessment will be performed on the baseline angiograms of the staged procedures in all the patients undergoing complete revascularization. Clinical follow-up will be performed at 30 days and 1 year from randomization.",[53,54,55,25],"Acute Coronary Syndromes (ACS)","NSTEMI - Non-ST-Segment Elevation Myocardial Infarction","STEMI - ST Elevation Myocardial Infarction",[57,58,59],"Murray-law based Quantitative Flow Ratio (μFR)","Non culprit vessel","Revascularization","NOT_YET_RECRUITING","2026-05-19",{"date":63,"type":30},"2026-05-22",{"date":65,"type":21},"2026-05-18",{"date":67,"type":21},"2028-06-30",{"name":69,"class":37},"University of Roma La Sapienza",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":48,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":85,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":4},"100640561","expand-management-of-blood-pressure-with-renal-denervation-in-patients-undergoing-staged-pci-for-advanced-coronary-artery-disease-100640561","NCT07602790","Expand Management of Blood Pressure With Renal Denervation in Patients Undergoing Staged PCI for Advanced Coronary Artery diseasE","Expand Management of Blood Pressure With Renal Denervation in Patients Undergoing Staged PCI for Advanced Coronary Artery Disease","EMBRACE","Inclusion Criteria:\n\n* Subject with multi-vessel disease\n* Having successful index PCI and planned staged procedure within 1-6 weeks to complete revascularization\n* Subjects ≥21 years of age\n* Office systolic blood pressure at index procedure and\u002For staged procedure (systolic blood pressure \\>140 mmHg) while taking 2 or more antihypertensive drugs\n* Subject agrees to have all study procedures performed, and is competent and willing to provide written, informed consent to participate in this clinical study prior to staged procedure\n\nExclusion Criteria:\n\n* \\- Contraindication for RDN outlined by IFU\n* Acute MI at time of the staged PCI procedure (AMI at time of the index PCI is allowed)\n* Subject has undergone prior renal denervation.\n* Subject has renal artery anatomy that is ineligible for RDN treatment per Symplicity Spyral™ IFU\n* Known secondary cause (e.g., renal artery stenosis, primary aldosteronism, pheochromocytoma, Cushing's syndrome, or other identifiable etiologies).\n* Severe renal failure (eGFR \\\u003C30 ml\u002Fmin\u002F1.73 m²)\n* Known LVEF \\\u003C30%\n* Known history of polycystic kidney disease, unilateral kidney, or undergone renal transplant\n* Mechanical circulatory support during PCI\n* Subject is under judicial protection, tutorship or curatorship\n* Failure of index procedure\n* Acute MI, severe renal failure, need for mechanical circulatory support, or legal incapacity between the index and staged procedures resulting in loss of eligibility.","21 Years",{"count":80,"type":21},1000,[50],"EMBRACE is a randomized, controlled, multicenter clinical study evaluating the effect of renal denervation on clinical adverse events in hypertensive patients undergoing staged percutaneous coronary intervention (PCI) for multivessel coronary artery disease.",[25,84],"Hypertension Resistant to Conventional Therapy",{"date":63,"type":30},{"date":87,"type":21},"2026-11",{"date":89,"type":21},"2033-11",{"name":91,"class":92},"Ceric Sàrl","INDUSTRY",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":48,"phases":103,"briefSummary":104,"conditions":105,"keywords":112,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":38},"100613651","surgical-versus-percutaneous-revascularization-in-patients-with-reduced-left-ventricular-function-stich-30-nl-100613651","NCT07269366","Surgical Versus Percutaneous Revascularization in Patients With Reduced Left Ventricular Function (STICH 3.0-NL)","Surgical Versus Percutaneous Revascularization in Patients With Reduced Left Ventricular Function","STICH 3*0-NL","Inclusion Criteria:\n\n* Age ≥ 18 years\n* LVEF≤ 40%\n* Angina pectoris, CCS≥2 and\u002For hospitalization for ACS or heart failure within 1 year prior to randomization\n* Multivessel CAD (2-3 vessel-disease with coronary lesions \\>70% and involvement of proximal LAD, and\u002For LM stenosis of \\>50%). Target vessels are determined by the local Heart Time\n* Clinical and angiographical characteristics suitable for isolated coronary revascularization both by CABG or PCI according to the judgment of the local Heart Team\n* Written informed consent\n\nExclusion Criteria:\n\n* ACS \\\u003C 48 hours before randomization\n* Valvular\u002Fstructural heart disease requiring intervention\n* Contra-indications to DAPT\n* Non-cardiac condition with life expectancy \\\u003C 1 year\n* Previous CABG\n* Decompensated HF at the time of inclusion",{"count":102,"type":21},358,[50],"This randomized multicenter trial compares coronary artery bypass grafting (CABG) with percutaneous coronary intervention (PCI) in 358 patients with ischemic left ventricular dysfunction and multivessel coronary disease. The study evaluates differences in survival, major cardiovascular events, and quality of life over 4 years, and contributes to the international STICH 3.0 collaboration assessing long-term outcomes.",[106,107,25,108,109,110,111,59],"Coronary Artery Disease","Coronary Artery Disease (CAD)","CABG","CABG in Low EF","Heart Failure","PCI",[113,114,115,116,117,118,119,120,121],"coronary artery","coronary artery disease","heart failure","low ejection fraction","hfref","cabg","coronary artery bypass graft","pci","revascularization","2026-05-07",{"date":124,"type":30},"2026-05-12",{"date":126,"type":21},"2026-05",{"date":128,"type":21},"2034-05",{"name":130,"class":37},"University Medical Center Groningen",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":139,"targetDuration":141,"studyType":22,"phases":4,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":38},"100630702","brazilian-prospective-registry-of-the-inspiron-evo-drug-eluting-stent-in-complex-coronary-lesions-100630702","NCT07491107","Brazilian Prospective Registry of the Inspiron EVO Drug-Eluting Stent in Complex Coronary Lesions","National Prospective Registry of the Inspiron EVO Drug-Eluting Stent in Complex Coronary Lesions","PCI EVOlution","Inclusion Criteria:\n\n* Individuals aged 18 years or older presenting with complex coronary lesions requiring percutaneous coronary intervention (PCI).\n* Individuals who provide consent and are willing to comply with the follow-up protocol.\n* Individuals who received treatment with the Inspiron™ EVO Stent.\n* Individuals with lesions ≥ 30 mm in length (Subprotocol 1).\n* Individuals with significantly calcified coronary lesions (moderate to severe according to the ACC\u002FAHA classification B1, B2, or C), with or without indication for lesion preparation techniques (Subprotocol 2).\n* Individuals with multivessel coronary artery disease (≥2 affected coronary vessels, with at least one vessel of small diameter ≤2.5 mm) (Subprotocol 3).\n* Individuals included in Subprotocol 1, 2, or 3. The evaluated segment must be accessible to the IVUS (Intravascular Ultrasound) catheter (Subprotocol 4).\n\nExclusion Criteria:\n\n* Lesions in saphenous vein grafts or internal mammary grafts.\n* Contraindication to the use of a drug-eluting stent.\n* Individuals who were treated during the index procedure with any stent other than the Inspiron™ EVO Stent.",{"count":140,"type":21},2000,"12 Months","The objective is to evaluate the efficacy and safety of the Inspiron™ EVO drug-eluting stent in complex coronary lesions in a real-world population. Patients with symptomatic ischemic heart disease due to lesions in native coronary arteries and restenotic lesions will be treated with the Inspiron™ EVO drug-eluting stent.",[107,144,145,25,146,147],"Stenosis Coronary","Small Vessel Ischemic Disease","Calcific Coronary Arteriosclerosis","Complex Coronary Lesions","2026-03-24",{"date":150,"type":30},"2026-03-30",{"date":152,"type":21},"2026-04-30",{"date":154,"type":21},"2030-04-30",{"name":156,"class":92},"Scitech Produtos Medicos SA",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":48,"phases":166,"briefSummary":167,"conditions":168,"keywords":170,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":187},"100156656","revascularization-strategies-in-patients-with-non-st-segment-elevation-acute-coronary-syndrome-nste-acs-and-severe-coronary-artery-disease-100156656","NCT01311323","Revascularization Strategies in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) and Severe Coronary Artery Disease","Multivessel and Left Main Coronary Artery Stenting in Comparison With Surgical Revascularization in Patients With Non ST Elevation Acute Coronary Syndrome. Prospective, Clinical Randomized Trial (The MILESTONE Trial)","MILESTONE","Inclusion Criteria:\n\nSubjects must meet ALL of the inclusion criteria to be considered for the trial. If ANY of the exclusion criteria are met, the subject is excluded from the trial and cannot be randomized.\n\n* Age over 18 years,\n* Written patient consent,\n* Acute Coronary Syndrome without ST-segment elevation of high, intermediate and low risk, including NSTEMI and unstable angina requiring urgent (within 72 hours) invasive strategy,\n* Qualification for invasive treatment,\n* Multivessel coronary disease, defined as angiographic narrowing \\>50%DS on investigator's visual assessment in at least two major coronary artery territories (RCA, LAD, LCX), including involvement of the proximal segment of the left anterior descending artery or three-vessel disease with a Syntax Score \\\u003C 33. Intermediate lesions (40-70%) will need to be assessed with either FFR, iFR, or VFFR). Patient may have left main coronary artery disease, defined as narrowing \\>50%DS (but this is not obligatory). For borderline changes, IVUS (MLA \\\u003C6 mm2 or iFR=\\\u003C0,90 or FFR=\\\u003C0,80, with an anatomic Syntax Score \\\u003C33 will be decisive,\n* Feasibility of complete revascularization on both the CABG and PCI sides,\n* Consent within the Heart Team for both CABG by the cardiothoracic surgeon and PCI by the interventional cardiologist.\n\nExclusion Criteria:\n\n* Age under 18 years,\n* ST-segment elevation myocardial infarction (STEMI) or new left bundle branch block (LBBB),\n* Stable coronary syndrome,\n* Single- or two-vessel coronary disease without involvement of the proximal LAD, defined as narrowing above 50%DS,\n* Qualification for conservative treatment,\n* Anticipated surgery other than CABG due to severe valvular defect or other structural defect, particularly moderate or severe mitral regurgitation,\n* Need for immediate coronary angioplasty treatment,\n* Syntax Score equal or above 33 (\\>=33),\n* Contraindications to short-term and long-term antiplatelet therapy,\n* Acute heart failure in class IV (cardiogenic shock),\n* Previous CABG procedure,\n* Previous PCI procedure within the last 6 months,\n* Ischemic or hemorrhagic stroke within 6 months prior to inclusion,\n* End-stage chronic kidney disease on dialysis,\n* Pregnancy or intention to become pregnant (women of child bearing age must have a recent negative pregnancy test prior to randomization),\n* Non cardiac co-morbidities with life expectancy less than 3 years,\n* Participation in other clinical trial that have not reached their primary endpoint.",{"count":80,"type":21},[50],"MILESTONE STUDY is dedicated to problems connected with patients with multivessel coronary artery disease and\u002For with left main narrowing who present symptoms of acute ischemia. For such kind of patients according to current ACC\u002FAHA guidelines CABG (surgical revascularization) is recommended as a treatment method. In comparison with CABG, recent studies have shown that PCI (percutaneous coronary intervention) is associated with a lower rate of periprocedural adverse events and similar long term event-free survival in patients with left main disease. Our latest non randomized registry and randomized LEMANS study, comparing LMCA (left main coronary artery) stenting with CABG confirmed above findings. LEMANS ACS (acute coronary syndrome) retrospective registry of patients with UPLMCA (unprotected LMCA) disease and non ST elevation ACS showed lower 30 day and trend toward lower one year mortality after PCI when compared with CABG. It should be stressed, that acute ischemia substantially increase the risk of CABG. In fact, there are limited data on the outcome of ULMCA stenting or CABG in patients with acute coronary syndromes (ACS).\n\nSimilarly, all randomized studies comparing PCI vs CABG in multivessel disease included mainly patients with stable angina, small cohort of patients with unstable angina and they excluded patients with non ST elevation Myocardial infarction.\n\nIn the SYNTAX study -largest PCI vs CABG trial, randomized patients were patients with low perioperative risk (logistic EUROSCORE \\\u003C5) and ACS patients routinely excluded. High perioperative risk patients were included only in PCI registry.",[25,169],"Acute Coronary Syndrome",[25,171,172,173,174,175,176,177],"Left Main Narrowing","Percutaneous Coronary Intervention","Coronary Artery Bypass Grafting","Drug-Eluting Stent","Fractional Flow Reserve","Instant wave-free ratio","virtual Fractional Flow Reserve","2026-02-20",{"date":180,"type":30},"2026-02-23",{"date":182,"type":30},"2025-08-25",{"date":184,"type":21},"2030-11",{"name":186,"class":37},"American Heart of Poland",7,{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":198,"conditions":199,"keywords":203,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":38},"100613307","for-patients-with-myocardial-infarction-and-multiple-vessel-testing-if-ultrasound-ufr-can-guide-all-needed-treatment-in-one-procedure-avoiding-a-return-hospital-visit-for-a-second-operation-100613307","NCT07264881","For Patients With Myocardial Infarction and Multiple Vessel: Testing if Ultrasound (UFR) Can Guide All Needed Treatment in One Procedure, Avoiding a Return Hospital Visit for a Second Operation.","A Prospective, Longitudinal, Multi-modal Study Evaluating the Utility of Acute Phase UFR (IVUS-FFR) to Predict Functional Significance in the Stable Phase for Patients With Acute Coronary Syndrome (ACS)","ACT-EVOLVE","Inclusion Criteria:\n\n* Age \\>18 years, any sex.\n* The participant is able to understand the study procedures and provides voluntary written informed consent.\n* Diagnosed with Acute Coronary Syndrome (ACS) and meets the criteria for one of the two pre-specified cohorts:\n* STEMI Cohort: Symptom onset \\\u003C 12 hours with ECG findings of ST-segment elevation myocardial infarction.\n* High-Risk NSTEMI Cohort: Meets at least one of the following: GRACE score \\> 140, dynamic ECG changes (ST-T), or significant Troponin elevation.\n* Has undergone successful emergency PCI of the Culprit Vessel (CV), with post-PCI TIMI flow Grade 3.\n* Coronary angiography confirms Multi-vessel Disease (MVD), defined as: at least one Non-Culprit Vessel (NCV) with a moderate stenosis (visual diameter stenosis 50-90%).\n* The target NCV (50-90% stenosis) is deemed by the investigator to be anatomically suitable for IVUS and pressure-wire assessment.\n* The participant agrees and is confirmed to be willing and able to strictly adhere to the protocol and complete all required invasive procedures, CMR scans, and follow-ups at the four timepoints (T0, T-CMR, T1, T2).\n\nExclusion Criteria:\n\n* Presence of cardiogenic shock on presentation, or persistent hemodynamic instability despite successful PCI of the culprit vessel.\n* Known severe allergy to iodinated contrast media or gadolinium-based contrast agents (used for CMR).\n* Female participants who are pregnant, breastfeeding, or planning pregnancy within the 1-year study period.Unprotected left main coronary artery disease (stenosis \\\u003C50%) requiring intervention.\n* Prior history of Coronary Artery Bypass Grafting (CABG) surgery.The target NCV has received prior PCI (e.g., existing stent) or surgical revascularization.\n* The target NCV is a Chronic Total Occlusion (CTO).\n* Severe renal insufficiency (eGFR \\\u003C 30 ml\u002Fmin\u002F1.73m²) or currently undergoing chronic dialysis.\n* Standard contraindications to CMR examination (e.g., claustrophobia, non-MRI-compatible metallic implants\u002Fpacemakers).\n* Known presence of a severe non-cardiac comorbidity with an expected lifespan of \\\u003C 12 months (e.g., advanced malignancy).\n* Known severe hematological disease (e.g., severe anemia, active bleeding, thrombocytopenia \\\u003C 70 x 10⁹\u002FL) rendering the participant unsuitable for multiple invasive procedures.\n* Inability to provide informed consent or comply with the complex longitudinal follow-up protocol due to psychiatric, cognitive, or other reasons.\n* Currently participating in another interventional (drug or device) clinical study.\n* Any other condition which, in the investigator's opinion, makes the participant unsuitable for enrollment (e.g., severe valvular heart disease, cardiomyopathy).",{"count":197,"type":21},200,"Brief Summary The Purpose of the Study : The purpose of this study is to find a safe and reliable \"one-stop\" solution for treating heart attack patients who have multiple blocked arteries. Currently, doctors face a dilemma: Testing these other blockages during the heart attack procedure is often unreliable.\n\nThe most accurate method requires asking the patient to return 30 days later for a second invasive procedure, which is a significant burden.\n\nThe Study's Hypothesis : We are testing a new tool called UFR, which uses ultrasound images to measure blockages. Our hypothesis (or \"educated guess\") is that this new UFR tool is not affected by the body's stress during a heart attack and can provide a true, reliable measurement right away.\n\nThe Question the Study is Trying to Answer ： The main question this study is trying to answer is: Can the new \"one-stop\" UFR tool, used during the initial heart attack procedure, accurately predict which blockages are truly serious... thereby eliminating the need for patients to return for a second procedure 30 days later? Researchers will also follow 200 patients for one year, using advanced scans (like UFR, standard tests, and MRI), to better understand how the heart and arteries heal and change over time.",[200,25,201,202],"Microvascular Obstruction (MVO)","ACS (Acute Coronary Syndrome)","ST Elevation Myocardial Infarction (STEMI)",[169,204,205,206,207,208,209,210,211,212,213,214,215,216],"Fractional Flow Reserve,","Intravascular Ultrasound","Virtual Fractional Flow Reserve","Functional Drift","Coronary Microvascular Dysfunction","Index of Microcirculatory Resistance","Non-Culprit Vessel","ST Elevation Myocardial Infarction","Non-ST Elevation Myocardial Infarction","Cardiac Magnetic Resonance","Microvascular Obstruction","Staged Revascularization","Computational Fluid Dynamics","2025-11-24",{"date":219,"type":30},"2025-12-04",{"date":221,"type":21},"2025-12-02",{"date":223,"type":21},"2028-06-22",{"name":225,"class":37},"Beijing Anzhen Hospital",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":48,"phases":235,"briefSummary":236,"conditions":237,"keywords":242,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":38},"100604453","temporary-mcs-with-the-ivac-2l-transaortic-device-in-high-risk-pci-100604453","NCT07149714","Temporary MCS With the iVAC 2L Transaortic Device in High-risk PCI","Temporary Mechanical Circulatory Support With the iVAC 2L Transaortic Device in High-risk Percutaneous Coronary Intervention","POTOK","Inclusion Criteria:\n\n* Multidisciplinary heart team consensus for high-risk PCI. HR-PCI was defined as any percutaneous intervention for coronary disease involving an unusually high risk of periprocedural circulatory collapse.\n* Signed Informed Consent to participate in the study\n\nExclusion Criteria:\n\n* Femoral artery diameter \\\u003C 6.0mm\n* Significant biventricular or right heart failure\n* Thrombus in the left ventricle\n* Presence of a mechanical aortic valve\n* Aortic valve stenosis\u002Fcalcification (equivalent to an orifice area of 0.6 cm2 or less) or moderate-to-severe aortic insufficiency (echocardiographic assessment graded as ≥+2)\n* Severe peripheral arterial disease precluding placement of the iVAC2L\n* Combined cardiorespiratory failure\n* Presence of an atrial or ventricular septal defect (including post infarct VSD)\n* Left ventricular rupture\n* Cardiac tamponade\n* Presence of any other subtype of shock\n* Known severe comorbidities independently affecting prognosis (chronic renal or liver failure, active malignancies etc.)\n* Recent major bleeding event (\\\u003C 3 months)\n* Recent stroke (\\\u003C 3 months)",{"count":20,"type":21},[50],"Patients with coronary artery disease and undergoing high-risk percutaneous coronary intervention (PCI) are at increased risk of hemodynamic instability and poor outcomes. Mechanical circulatory support (MCS) devices may offer hemodynamic stabilization during PCI, potentially improving short- and long-term outcomes. The study rationale is to investigate the safety and clinical efficacy of temporary MCS with the iVAC 2L transaortic device in high-risk percutaneous coronary intervention.\n\nThe transaortic system for short-term circulatory support with pulsatile blood flow iVAC 2L consists of an external membrane pump, a 17Fr diameter catheter for reversed blood flow (intake cannula) with a patented two-way rotary valve.\n\nThe pump has two chambers, one for blood and one for helium, separated by a flexible diaphragm. The blood chamber connects to the catheter and the air chamber connects to a standard IABP console. The bi-directional valve is located 72 mm from the aspiration tip of the catheter and determines the direction of blood flow. The catheter is advanced retrogradely through the common femoral artery so that the tip is located in the left ventricular (LV) cavity and the valve is in the ascending aorta. Synchronized with the cardiac cycle via ECG, the device draws blood from the LV into the pump chamber during systole and ejects blood from the pump into the ascending aorta during diastole.\n\nThe primary composite outcome is all-cause mortality, including acute myocardial infarction, stroke and TIA during hospitalization and at Day 360 of follow-up, expressed as a percentage of total patients.",[238,25,106,239,240,241,172],"Ischemic Cardiovascular Disease","Cardiogenic Shock","Acute Heart Failure (AHF)","Chronic Heart Failure",[243,244,245],"Mechanical circulatory support","High-Risk Percutaneous Coronary Intervention","Coronary artery disease","2025-08-29",{"date":248,"type":30},"2025-09-08",{"date":250,"type":30},"2023-02-17",{"date":252,"type":21},"2029-02-17",{"name":254,"class":255},"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","OTHER_GOV",{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":265,"conditions":266,"keywords":268,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":281},"100603243","stich3c-cardiac-magnetic-resonance-observational-study-100603243","NCT07133984","STICH3C Cardiac Magnetic Resonance Observational Study","STICH3C Cardiac Magnetic Resonance (CMR) Observational Study (STICOS)","STICOS","Inclusion Criteria:\n\n1. Men and women ≥ 18 years old\n2. LVEF ≤ 40% (quantified by echo, single-photon emission computed tomography \\[SPECT\\], or CMR within 2 months of enrollment)\n3. Prognostically important CAD: either multivessel CAD (triple vessel or double vessel CAD including left anterior descendant artery (LAD), significant coronary stenosis defined as ≥ 70% based on coronary angiography, fractional flow reserve (FFR) ≤ 0.80 or instantaneous wave-free ratio (iFR) ≤ 0.89) or left main disease (+\u002F- other CAD) for which significant stenosis defined as \\> 50% based on coronary angiography, intravascular ultrasound (IVUS) minimum luminal area \\[MLA\\] value ≤ 6.0 mm2 (\\\u003C 4.5 mm2 Asian descent), or equivalent optical coherence tomography (OCT) measurements.\n4. Planned CABG or PCI within 3 months\n\nExclusion Criteria:\n\n1. Concomitant valve disease or other condition (e.g., LV aneurysm) requiring surgical repair or replacement\n2. Contraindication to CMR (i.e. magnetically activated materials), gadolinium, regadenoson\u002Fadenosine\u002Fdipyridamole\n3. Active neoplasm and\u002For severe end-organ dysfunction with expected life expectancy less than 5 years.\n\n   \\-",{"count":197,"type":21},"STICOS will test the hypothesis that residual jeopardized myocardium, late gadolinium enhancement, and non-ischemic substrate after revascularization is associated with postoperative adverse cardiovascular events such as heart failure , readmission, or death.\n\nThis study will look at whether certain heart tissue abnormalities seen on MRI scans can help predict serious health problems after heart procedures like stents or bypass surgery.",[267,25],"Ischemic Left Ventricle Systolic Dysfunction",[269,270,271],"iLVSD","CAD","Cardiac MRI","2025-08-14",{"date":274,"type":30},"2025-08-21",{"date":276,"type":30},"2024-03-01",{"date":278,"type":21},"2030-01",{"name":280,"class":37},"Weill Medical College of Cornell University",9,{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":286,"acronym":287,"eligibilityCriteria":288,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":48,"phases":291,"briefSummary":292,"conditions":293,"keywords":295,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":281},"100546847","multivessel-balloon-occlusion-to-investigate-obstructive-coronary-artery-disease-and-angina-100546847","NCT06400290","Multivessel Balloon Occlusion to Investigate Obstructive Coronary Artery Disease and aNgina","ORBITA-MOON","Inclusion Criteria:\n\n* Eligibility for PCI due to angina\n* Anatomical evidence of significant multi-vessel coronary stenosis defined by either:\n\n  1. ≥70% stenosis in two or more coronary arteries of ≥2.5mm visual diameter stenosis, on invasive coronary angiography (ICA)\n  2. Severe stenosis in ≥2 coronary arteries of ≥ 2.5mm visual diameter stenosis, on CTCA\n* Physiological evidence of ischaemia with a positive test corresponding to the coronary arteries to be stented, on at least one of the following:\n\n  * dobutamine stress echocardiogram\n  * cardiac MRI\n  * myocardial perfusion study\n  * invasive metrics of coronary physiology\n\nExclusion Criteria:\n\n* Recent acute coronary syndrome\n* Previous coronary artery by-pass graft surgery (CABG)\n* Significant left main stem disease\n* Chronic total occlusion in the target artery(s)\n* Moderate to severe valvular disease\n* Moderate to severe left ventricular impairment\n* Contraindication to PCI or a drug-eluting stents\n* Contraindication to antiplatelet therapy\n* Contraindication to adenosine\n* Pregnant\n* Inability to consent",{"count":290,"type":21},60,[50],"ORBITA-MOON is a double-blinded, placebo-controlled experimental study that aims to understand how the different coronary artery stenoses contribute to overall clinical angina in patients with multi-vessel coronary artery disease. This study will investigate the symptoms conferred by each stenosis, induced by experimental ischaemia, for 60 patients with multi-vessel coronary artery disease.",[294,25],"Stable Angina",[296,297,298,299],"Angina","Multi-vessel coronary artery disease","Symptoms","Placebo-controlled symptom assessment","2025-06-05",{"date":302,"type":30},"2025-06-06",{"date":304,"type":30},"2024-06-13",{"date":306,"type":21},"2027-04",{"name":308,"class":37},"Imperial College London",{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":316,"targetDuration":4,"studyType":48,"phases":318,"briefSummary":319,"conditions":320,"keywords":324,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":38},"100587476","ticin-pilot-study-sirolimus-eluting-balloon-for-stabilization-and-regression-of-non-obstructive-coronary-plaques-100587476","NCT06928883","Ticin Pilot Study: Sirolimus-Eluting Balloon for Stabilization and Regression of Non-Obstructive Coronary Plaques.","TITAN-PARADISE Pilot: TicIn for the Treatment of Coronary Lesions - Plaque Regression and Stabilization With Sirolimus Elution (Pilot Study)","Inclusion Criteria:\n\nPotential subjects must fulfill all following inclusion criteria:\n\n1. Multivessel coronary artery disease with ACS within 90 days prior to inclusion and successful interventional treatment of the culprit lesion\n2. Presence of ≥ 2 de novo non-culprit lesion without hemodynamic relevance in two different coronary vessels (demonstrated either by wire-based or angiography-based coronary physiology) and with MaxLCBI4mm ≥ 325 at baseline IVUS-NIRS\n3. Age ≥ 18 years\n4. Written informed consent\n\nExclusion Criteria:\n\nPatients are not eligible if any of the following applies:\n\n1. Non culprit lesion involving the left main and\u002For ostial left coronary artery, ostial left circumflex artery or ostial right coronary artery;\n2. Non-culprit lesion in a previously stented segment (i.e. within 15 mm from the previously implanted stent);\n3. Non-culprit lesion involving small vessel (\\\u003C3.0 mm) deemed not suitable to PCI,\n4. Non-culprit lesion located in a bypass graft or in a grafted vessel;\n5. Severe renal impairment (eGFR\\\u003C15ml\u002Fmin\u002F1.73m2) or patient on dialysis treatment;\n6. Known pregnancy r breast-feeding patients;\n7. Life expectancy \\\u003C2 year due to other severe non-cardiac disease;\n8. Legally incompetent to provide informed consent;\n9. Partecipation in another clinical study with an investigational product",{"count":317,"type":21},24,[50],"The goal of this pilot clinical trial is to evaluate the use of the Selution SLR sirolimus-eluting balloon, in addition to guideline-directed medical therapy (GDMT), for the preventive treatment of non-flow-limiting vulnerable coronary lesions, compared to GDMT alone, in adult patients with multivessel coronary artery disease and a recent acute coronary syndrome (within 90 days).\n\nThe main research question is:\n\nDoes the use of the Selution SLR sirolimus-eluting balloon in combination with GDMT reduce the progression and vulnerability of non-flow-limiting vulnerable coronary plaques?\n\nParticipants will undergo\n\n* PCI procedure with baseline IVUS-NIRS assessment\n* Follow-up coronary angiography at 6 months with IVUS-NIRS assessment\n* Clinical follow-up at 3, 6, and 24 months after study enrollment",[321,322,25,323,53],"Coronary Arterial Disease (CAD)","Vulnerable Coronary Plaques","Coronary Vessel",[321,322,325,326,53,327,328,329,330,331,332,333,334],"Multivessel coronary artery disease","Coronary vessel","Non-flow limiting vulnerable coronary plaques","Sirolimus-eluting DEB","DEB Selution SLR","Guidelines-directed medical therapies (GDMT)","IVUS-NIRS","MaxLCBI4mm","MaxLCBI4mm≥325","Lipid Core Burden Index (LCBI)","2025-04-08",{"date":337,"type":30},"2025-04-15",{"date":339,"type":21},"2025-04",{"date":341,"type":21},"2028-12-31",{"name":343,"class":37},"Cardiocentro Ticino",{"id":345,"slug":346,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":48,"phases":354,"briefSummary":355,"conditions":356,"keywords":358,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":371},"100499659","complete-revascularization-versus-culprit-lesion-only-pci-in-nstemi-100499659","NCT05786131","Complete Revascularization Versus Culprit Lesion Only PCI in NSTEMI","Complete Revascularization Versus Culprit Lesion Only PCI in NSTEMI (-COMPLETE-NSTEMI-)","CompleteNSTEMI","Inclusion Criteria:\n\n* NSTEMI as suggested by high-sensitivity troponin algorithms\n* Multivessel coronary artery disease\n* Identifiable culprit lesion\n* Informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Cardiogenic shock\n* Sustained ventricular tachycardia (VT) or ventricular fibrillation (VF)\n* Contraindication for coronary revascularization\n* Prior coronary artery bypass graft\n* Indication for coronary artery bypass graft surgery\n* Non-culprit lesion located in the left main coronary artery\n* Co-morbidity with life expectancy less than 6 months\n* Type 2 myocardial infarction\n* Pregnancy and breast feeding period",{"count":353,"type":21},3390,[50],"Prospective, randomized, controlled, multicenter, open-label trial to study whether multivessel percutaneous coronary intervention (PCI) is superior over culprit-lesion only PCI in patients with non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel coronary artery disease.",[357,25],"Non-ST-elevation Myocardial Infarction",[359,325,360,361],"NSTEMI","culprit-lesion only PCI","multivessel percutaneous coronary intervention","2025-01-15",{"date":364,"type":30},"2025-01-16",{"date":366,"type":30},"2023-10-27",{"date":368,"type":21},"2027-07-31",{"name":370,"class":37},"Leipzig Heart Science gGmbH",58,{"id":373,"slug":374,"hasResults":11,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":48,"phases":382,"briefSummary":383,"conditions":384,"keywords":385,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":4},"100545198","robotically-assisted-minimally-invasive-direct-coronary-artery-bypass-with-stenting-randomized-against-coronary-artery-bypass-graft-surgery-100545198","NCT06378775","Robotically-assisted Minimally-invasive Direct Coronary Artery Bypass With Stenting, Randomized Against Coronary Artery Bypass Graft Surgery","Robotically-assisted Minimally-invasive Direct Coronary Artery Bypass With Stenting, Randomized Against Coronary Artery Bypass Graft Surgery: a Pilot Trial","ROBOT RCT","Inclusion Criteria:\n\n1. Multi-vessel CAD with an indication for revascularization,\n2. Presence of at least 1 risk factor for increased risk of post-operative death or major complication,\n\n   * Any patient Age \\> 80, OR\n   * Any patient with eGFR (Glomerular Filtration Rate) \\\u003C 50, OR\n   * Any patient with LVEF \\\u003C 40%, OR\n   * Any patient deemed to be \"frail\" by consulting surgeon. OR\n   * Patients \\> 75 years of age with at least one of the following:\n\n     * Ejection fraction \\\u003C 50%\n     * History of prior CVA (Cerebral Vascular Accident)\n3. Coronary artery anatomy appropriate for a robotically-assisted MIDCAB or regular CABG, vessels other than the left anterior descending with lesions amenable to either CABG or PCI.\n\nExclusion criteria\n\n1. Significant left main coronary artery disease,\n2. Ejection fraction \\\u003C 30%,\n3. Patients with GFR \\\u003C 30,\n4. Patients unable to take dual anti-platelet agents due to high bleeding risk,\n5. Patients requiring emergent surgery, including patients with hemodynamic instability,\n6. Patients with anatomy not suitable for a robotically-assisted approach (by CT chest).",{"count":381,"type":21},80,[50],"The study objective is to compare standard CABG to a hybrid revascularization strategy (RA-MIDCAB + PCI) in patients who have multi-vessel CAD and an indication for surgery, but who have a slightly higher risk of post-operative complications.",[106,25],[108,386,387,388],"Hybrid Coronary Revascularization","Robotically-assisted minimally-invasive direct coronary artery bypass","RA-MIDCAB","2024-04-21",{"date":391,"type":30},"2024-04-23",{"date":393,"type":21},"2024-05-01",{"date":395,"type":21},"2028-12-01",{"name":397,"class":37},"Cardiology Research UBC",{"id":399,"slug":400,"hasResults":11,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":48,"phases":407,"briefSummary":408,"conditions":409,"keywords":411,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":4},"100490676","the-favor-v-ami-trial-100490676","NCT05669222","The FAVOR V AMI Trial","Functional and Angiography-Derived Strain Guided Multi-Vessel\u002FLesion Revascularization Strategy in Patients With Acute ST-Segment Elevation Myocardial Infarction (FAVOR V AMI)","Inclusion Criteria:\n\n* General inclusion\n\n  1. Age ≥18 years\n  2. STEMI ≤30d\n  3. Successful primary PCI of all culprit lesion(s) responsible for the STEMI (visually-assessed residual stenosis \\\u003C30% in stent-treated lesions or \\\u003C50% in DCB-treated or PTCA-treated lesions, with TIMI-3 flow in all treated vessels)\n  4. No MACE event between the index PCI and the staged randomized procedure\n  5. Able to understand the trial design and provide written informed consent\n* Angiographic inclusion:\n\n  1. The presence of at least 1 non-culprit lesion with DS% 50%-90% in any non-infarct related artery with RVD ≥2.5 mm by visual assessment\n  2. Non-culprit lesions are potentially eligible for PCI Note: All lesions in the infarct related arteries with DS ≥70% and RVD ≥2.5 mm by visual assessment must be successfully treated either during the index primary PCI or the staged procedure prior to randomization Note: There may also be 1 or more NCL with DS% \\>90% (including a CTO) as long as there is at least 1 NCL with DS% 50%-90% as above. Any such lesions in which PCI is intended must be treated successfully either during the index primary PCI or the staged procedure prior to randomization.\n\nExclusion Criteria:\n\n* General exclusion\n\n  1. Cardiogenic shock or refractory hypotension (Killip IV)\n  2. On pressors or use of or need for intra-aortic balloon pump or other mechanical circulatory support devices\n  3. Intubated\n  4. Prior thrombolytic therapy for this admission\n  5. Cockcroft-Gault-calculated CrCl \\\u003C30 ml\u002Fkg\n  6. Pregnant or woman of child-bearing potential\n  7. Life expectancy less than 1 year for non-cardiac causes\n  8. Allergy to iodine-containing contrast agents which cannot be adequately premedicated\n  9. Unable to tolerate DAPT for at least 6 months\n  10. Prior CABG or planned CABG\n  11. Any planned surgery within 6 months\n  12. Any condition that may interfere with any follow-up procedures (e.g. dementia, drug use)\n* Angiographic exclusion\n\n  1. Poor angiographic image quality precluding vessel contour detection or with suboptimal contrast opacification, branch ostium cannot be shown clearly, severe overlap in the stenosed segment or severe tortuosity of any interrogated vessel deemed not amenable to μQFR or RWS measurement\n  2. Unable to judge culprit lesion or infarct-related artery according to current evidence",{"count":406,"type":21},5000,[50],"The FAVOR V AMI study is a prospective, multicenter, blinded, randomized, sham-controlled trial comparing the long-term clinical outcomes of the \"Functional and Angiography-derived Strain inTegration (FAST)\" technique (next-generation quantitative flow ratio \\[μQFR\\] and radial wall strain \\[RWS\\]) guided percutaneous coronary intervention (PCI) strategy, with standard treatment strategy, in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary disease (MVD).",[410,25,172],"ST-Segment Elevation Myocardial Infarction",[412,410,25,172,413],"Quantitative Flow Ratio","Radial Wall Strain","2023-09-10",{"date":416,"type":30},"2023-09-13",{"date":418,"type":21},"2023-09-30",{"date":420,"type":21},"2028-06",{"name":422,"class":255},"China National Center for Cardiovascular Diseases",{"id":424,"slug":425,"hasResults":11,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":430,"enrollmentInfo":431,"targetDuration":4,"studyType":48,"phases":433,"briefSummary":434,"conditions":435,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":4},"100503431","complete-revascularization-via-inferior-part-sternotomy-100503431","NCT05835167","Complete Revascularization Via Inferior Part-sternotomy","Minimally Invasive Coronary Artery Bypass Grafting Achieving Complete Revascularization of Multivessel Coronary Artery Disease Via Inferior Part-Sternotomy (The ACRIS-MICABG Trial)","Inclusion Criteria:\n\nPatients who undergo primary isolated open-chest CABG with multi-vessel coronary disease(left main artery disease with right coronary artery disease,or three-vessel disease)\n\nExclusion Criteria:\n\n1. Single vessel disease, double vessel disease, left main artery disease without right coronary artery disease.\n2. Concomitant cardiac surgeries(i.e. valve repair or replacement, Maze surgery, left ventricular repair due to ventricular aneurysm).\n3. Redo CABG.\n4. Emergent CABG.\n5. Left ventricular ejection fraction(EF≤35%).\n6. Severe atherosclerosis of the ascending aorta.\n7. Subjects tend to choose surgical approach (via full median sternotomy\u002Finferior part-sternotomy) .\n8. Malignant tumor or other severe systemic diseases.\n9. Severe renal insufficiency (i.e. creatinine \\>200 μmol\u002FL).\n10. Contraindications for dual antiplatelet therapy, such as active gastroduodenal ulcer.\n11. Participant of other ongoing clinical trials.","80 Years",{"count":432,"type":21},260,[50],"To verify the effectiveness and safety of minimally invasive coronary artery bypass grafting for complete revascularization of multivessel coronary artery disease via inferior part-sternotomy, We aim to randomize 260 patients undergoing isolated Coronary artery bypass grafting (CABG) to compare the ratios of complete revascularization between inferior part-sternotomy CABG and full median sternotomy CABG from 9 hospitals in China.",[436,173,25],"Complete Revascularization","2023-04-27",{"date":439,"type":30},"2023-04-28",{"date":441,"type":21},"2023-05-05",{"date":443,"type":21},"2035-05-04",{"name":422,"class":255}]